Italy· 050080011
VYDURA*2x1 liofilizzati OS 75 mg dose unitaria
A rimegepant product containing rimegepant, registered in Italy by PFIZER EUROPE MA EEIG, on the national reimbursement list. The same ATC class is registered in 16 of our 19 countries.
Checked against the register on
Informational only — not a medical device.
Where it is registered
Rimegepant is registered in 16 of 19 countries.
Countries holding a registration under ATC N02CD06 (rimegepant), each read from that country’s own register.
- This record: Italy
- 11 of them publish a price we can compare per daily dose
Rimegepant · ATC N02CD06
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of rimegepant costs, country by country.
Normalised to the WHO defined daily dose (37.5 mg), the median price runs from $14.84 in Switzerland to $64.33 in United States — a ×4.3 gap.
- Italy: $18.89 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Rimegepant · price per daily dose (37.5 mg)
USD · FX 28 Sept 2026
- US United States$64.33 (acquisition cost)
- IT Italy$18.89
- ES Spain$16.29
- CH Switzerland$14.84
The record
At a glance
- Active substance
- Rimegepant
- Manufacturer
- PFIZER EUROPE MA EEIG
- Country
- Italy (IT)
- ATC code
- N02CD06
- ATC class
- Rimegepant
- Defined daily dose
- 37.5 mg, O
- Reimbursed
- Yes
- Last checked
- June 4, 2026
Packs & prices · 1
1 priced- aic050080011VYDURA*2x1 liofilizzati OS 75 mg dose unitariaEUR 66.36
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
90 interactions on record for rimegepant.
Graded by severity as the source publishes them — 9 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Rimegepant · interactions on record
90 records
- 9 severe
- 81 moderate
Most severe, free to view
- DexamethasoneH02AB02severe
- DabrafenibL01EC02severe
- LorlatinibL01ED05severe
- DabrafenibL01XE23severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Rimegepant in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesNURTEC ODTPfizer Laboratories Div Pfizer Inc
- CzechiaVYDURAPfizer Europe MA EEIG, Bruxelles
- SwitzerlandVydura 75 mg, Lyophilisat zum EinnehmenPfizer AG
- FranceVYDURA 75 mg, lyophilisat oralPFIZER EUROPE MA EEIG (BELGIQUE)
- United KingdomVydura 75mg oral lyophilisatesPfizer Ltd
- BelgiumVydura 75 mgPfizer Europe MA
- IcelandVyduraPfizer Europe MA EEIG*
- NetherlandsVydura 75 mg, lyofilisaat voor oraal gebruikPfizer Europe MA EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vydura
- Liechtenstein · Vydura
- Norway · Vydura
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b9797499-c24e-4e51-a438-a1dc15ec9378 GET /v1/drugs/b9797499-c24e-4e51-a438-a1dc15ec9378?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"price": 66.36,
"source": "aifa",
"currency": "EUR",
"strength": "RIMEGEPANT 75MG 2 UNITA' USO ORALE",
"substance": "Rimegepant",
"equivalence_group": "MGX",
"transparency_flag": null
}See everything about rimegepant.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.